Nathalie Lamichhane-Bonichon - Publications

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Journal: NPJ precision oncology

Published: November 21, 2025

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Journal: Translational oncology

Published: September 29, 2025

Unusual Site of Solitary PSMA-Positive Recurrence of Prostate Cancer in an Undescended Testis.

Journal: Clinical nuclear medicine

Published: July 08, 2025

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.

Journal: Molecular cancer

Published: May 13, 2024

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.

Journal: JAMA oncology

Published: April 04, 2024

Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 29, 2024

Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 20, 2024

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 05, 2024

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Journal: Breast cancer research and treatment

Published: October 18, 2023

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Journal: Cancers

Published: February 19, 2023

Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.

Journal: Gynecologic oncology

Published: November 21, 2022

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 23, 2020